Dexmedetomidine Sedation in Children With Respiratory Morbidities

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

19 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-11-30

Study Completion Date

2015-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aimed to determine the feasibility of dexmedetomidine in children with respiratory morbidities who required deep sedation for magnetic resonance imaging (MRI) scans.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Oral Dexmedetomidine in Pediatric MRI

NCT05619627

Anesthesia

NOT_YET_RECRUITING PHASE1

Intra-nasal Dexmedetomidine for Children Undergoing MRI Imaging

NCT03806777

MRI Sedation

UNKNOWN PHASE4

Intranasal Dexmedetomidine Sedation at Dose of 2 mcg/kg Versus 4 mcg/kg in Children Undergoing MRI

NCT05091151

Anesthesia Deep Sedation Magnetic Resonance Imaging +1 more

COMPLETED NA

Dexmedetomidine Sedation in Children Before MRI Examinations

NCT05163704

Deep Sedation

COMPLETED NA

Safety Evaluation of Propofol Sedation for Magnetic Resonance Imaging in Pediatric Patients

NCT04455776

Multiparametric Magnetic Resonance Imaging Propofol Adverse Reaction Sedation Complication +1 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Electronic medical records of children with at least 3 characteristics of respiratory morbidities were retrospectively reviewed. All study patients received dexmedetomidine bolus over 10 min followed by a continuous infusion to achieve a minimum Ramsay Sedation Score of 5. Patients were monitored for hemodynamics, total dose of dexmedetomidine received, adverse events experienced and sedation characteristics.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Respiratory Morbidity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dexmedetomidine

Children up to the age of 16 years requiring MRI under deep sedation with at least 3 characteristics of respiratory morbidities were identified as having increased risk for adverse respiratory events. Dexmedetomidine was administered as a first bolus of 1 mcg•kg-1 over 10 min, followed by a continuous infusion at 1.0 mcg•kg-1•h-1. Sedation level was assessed by Ramsay Sedation Scale and it was initially recorded at 1-min interval. If the child failed to achieve a minimum RSS of 5, this bolus was repeated once again and the continuous infusion was subsequently increased to 2 mcg•kg-1•h-1. In addition, propofol 0.5 mg.kg-1 iv. was allowed to be administered, in patients still exhibiting movement that could interfere with image acquisition.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Dexdor

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Children up to the age of 16 years with at least 3 characteristics of respiratory morbidities

Exclusion Criteria

* Children who had an American Society of Anaesthesiologists (ASA) physical status classification IV
* Documented pre-existing cardiac conduction abnormalities
* Renal impairment

Minimum Eligible Age

1 Month

Maximum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No